EDIT News and Press, Editas Medicine Inc. From 02/04/23

In stock investing, it's easy to focus on big names and blue-chip companies since they are frequently reported in financial media. Conversely, smaller companies, but with promising businesses, tend to be ignored. The latter have smaller market capitalizations and usually trade at more affordable ...

Shares of Editas Medicine (NASDAQ: EDIT) were up 21.1% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The gene-editing biotech has actually had a two-week run. Its shares have climbed 48.7% since January 19, the day it announc...

With shares down by 60% in the last three years, Editas Medicine (NASDAQ: EDIT) investors are experiencing a bumpy ride despite the company's impeccable gene-editing credentials. But for a biotech that's in the running to be one of the world's leading gene-therapy developers, share prices...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health. Using CRISPR, scientists can slice int...

Shares of gene-editing company Editas Medicine (NASDAQ: EDIT) rose by a healthy 11.5% over the course of January, according to data provided by S&P Global Market Intelligence . This big monthly gain stemmed from a definitive agreement between Editas and privately held Shorelin...

Editas Medicine ( NASDAQ: EDIT ), Intellia Therapeutics ( NASDAQ: NTLA ), and Beam Therapeutics ( NASDAQ: BEAM ) were among clinical-stage biotechs to receive Overweight ratings at Cantor Fitzgerald as the firm launched its coverage on several gene editing companies. T...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis. As a result, c...

Summary The implications of upcoming payor decisions and profitability dynamics for BLUE's therapies will have industry-wide ramifications as peers prepare to follow suit with their newly-developed therapies targeting rare-genetic diseases. Despite the high price of BLUE's therapies, I ...

Shares of Editas Medicine (NASDAQ: EDIT) were up 12.7% this week, as of Thursday's close, according to data provided by S&P Global Market Intelligence . The biotech specializes in gene-editing therapies, and its shares are down more than 50% over the past year. This week w...

Editas Medicine ( NASDAQ: EDIT ) announced an agreement with privately-held Shoreline Biosciences on Thursday to sell its natural killer cell ((iNK)) programs and related manufacturing technologies. As part of the deal, Shoreline will also obtain an exclusive license to Editas’...